Abstract: An ambient pressure compensation structure for an ultraviolet difference spectrum gas sensor includes a closed box, an ultraviolet difference spectrum gas sensor, a digital pressure sensor, a thermostatic controller, an industrial control computer, a pressure regulating assembly and a limiting partition; the pressure regulating assembly and the limiting partition are arranged inside the closed box, the pressure regulating assembly comprises a piston, a regulating rod and a driving motor, the left side of the piston is connected with the regulating rod, the front end of the regulating rod penetrates out of the closed box and is connected with the driving motor, and the piston divides the interior of the closed box into a pressure regulating air chamber and a working air chamber. Also disclosed is an ambient pressure compensation method for an ultraviolet difference spectrum gas sensor.

Abstract: A method of imaging acrylic glass is presented. An image is formed on a transfer sheet or medium, and is heat transferred to the acrylic glass substrate on which the image is to permanently appear. An opaque pass-through coating is applied to one surface of the clear or transparent acrylic glass article. Heat activatable dye forms the image, and the heat activatable dye, when heat activated in close relationship to the opaque pass-through coating, passes through the opaque pass-through coating to the acrylic glass substrate. The image reflects light through the acrylic glass and is visible through the material and from the side opposite the opaque coating. The opaque pass-through coating layer permanently bonds to the acrylic glass surface.

Abstract: A transfer medium is provided for receiving images formed on the medium by inks or toners comprising thermally diffusible colorants, including disperse dye and sublimation dye, and methods of using the medium to present images on substrates. The medium provides an opaque layer that allows transfer of the image from the medium to a substrate, and provides a background for the image when the image is transferred to a dark colored substrate, so that the dark colored substrate does not obscure the image.

Abstract: A method of imaging thermoplastics, such as acrylic glass, is presented. An image is formed on a transfer sheet or medium, and is heat transferred to the acrylic glass substrate on which the image is to permanently appear. An opaque pass-through coating is applied to one surface of the clear or transparent acrylic glass article. Heat activatable dye forms the image, and the heat activatable dye, when heat activated in close relationship to the opaque pass-through coating, passes through the opaque pass-through coating to the thermoplastic substrate. The image reflects light through the thermoplastic material and is visible through the material and from the side opposite the opaque coating. The opaque pass-through coating layer permanently bonds to the acrylic glass surface.

Abstract: A transfer medium is provided for receiving images formed on the medium by inks or toners comprising thermally diffusible colorants, including disperse dye and sublimation dye, and methods of using the medium to present images on substrates. The medium provides an opaque layer that allows transfer of the image from the medium to a substrate, and provides a background for the image when the image is transferred to a dark colored substrate, so that the dark colored substrate does not obscure the image.

Abstract: This invention is a process of printing or forming a resist layer over an area of a printed transfer medium that has binders or other materials thereon but is not covered by a printed image. The layer resists transfer to the final substrate of binder materials and other materials of the transfer medium that are not covered with the printed image.

Abstract: The present invention provides a method for making glycoside compounds including the steps of: (a) lithiating an aromatic reactant having a leaving group using a lithium reagent in a first microreactor under non-cryogenic conditions to form a lithiated anion species, and (b) coupling the lithiated anion species with a carbonyl substituted reactant to form a glycoside.

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.

Abstract: The present invention provides a method for making glycoside compounds including the steps of: (a) lithiating an aromatic reactant having a leaving group using a lithium reagent in a first microreactor under non-cryogenic conditions to form a lithiated anion species, and (b) coupling the lithiated anion species with a carbonyl substituted reactant to form a glycoside.

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula 1

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: The present invention relates to a process for the preparation of epothilone analogs by initially forming novel ring-opened epothilones and carrying out a macrolactamization reaction thereon. The subject process is amenable to being carried out in a single reaction vessel without isolation of the intermediate compound and provides at least about a three-fold increase in yield over prior processes for preparing the desired epothilone analogs.

Abstract: The present invention relates to a process for the preparation of epothilone analogs by initially forming novel ring-opened epothilones and carrying out a macrolactamization reaction thereon. The subject process is amenable to being carried out in a single reaction vessel without isolation of the intermediate compound and provides at least about a three-fold increase in yield over prior processes for preparing the desired epothilone analogs.

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula 1

Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: The present invention relates to a process for the preparation of epothilone analogs by initially forming novel ring-opened epothilones and carrying out a macrolactamization reaction thereon. The subject process is amenable to being carried out in a single reaction vessel without isolation of the intermediate compound and provides at least about a three-fold increase in yield over prior processes for preparing the desired epothilone analogs.